Can geriatric patients take EXJADE?
Clinical trials for EXJADE did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects or have a different adverse event profile from younger patients. Thirty patients 65 years or older were included in clinical trials of EXJADE. The majority of these patients had myelodysplastic syndrome (n=27). In general, caution should be used in elderly patients due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
